Zocdoc CEO: 3 ways healthcare will change next year

The latest stories trending on MedCity News.

Editor's Pick

Top Story Zocdoc CEO Predicts 3 Ways the Healthcare Industry Will Change in 2025 Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 — including the rise of cash-pay services and the potential restructuring of Amazon's healthcare assets. Sponsored Turn Underutilized Healthcare Data Into Revenue- Through Pharma Collaborations Presented by datma datma.FED, a federated Real-World data platform, empowers health systems and labs to: Unlock Sustainable Revenue: Earn ongoing revenue through a scalable shared-upside model Stay in Control: Keep full control over data access, privacy, and compliance Drive Strategic Growth: Reinvest in innovation, offset costs, and fund internal initiatives Learn more about the revenue model and upcoming onboarding window with datma. Calling All Startups! Pitch at INVEST 2025 Showcase your innovation at INVEST 2025 in Chicago on 20-21 May and compete for a $20,000 advertising credit on MedCityNews.com!  Take this opportunity to pitch in front of leading investors and industry professionals.  Deadline: Apply by January 10, 2025 Apply Today

Featured News

Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder Neurocrine Biosciences' Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. How One Company is Using an Armband to Combat the Overdose Crisis Ayuda Medical offers a wearable device that can detect an overdose and call for help. The company has received support from the NIH and NIDA via the Small Business Innovation Research program. Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site Novo Nordisk's new Denmark site will produce drugs for rare diseases, such as hemophilias. Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings' acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. Facilities Built for the Future: 3 Healthcare Design Trends Emerging in 2025 and Beyond Whether pursuing high-tech solutions, tapping into natural elements, or doubling down on smaller building sizes, the future of healthcare facilities design boils down to improving patient access and nurturing employee retention. Healthcare Organizations Can, and Should, Provide Continuous Patient Care with the Right Technology Now, more than ever, healthcare organizations must strive to innovate to ensure continuous patient care delivery while keeping medical staff safe.

Resources

SPONSORED MedCity Pivot Podcast: Self-insured Employers Weigh Benefits of GLP-1 Drugs In a conversation with MedCity News Editor-in-Chief Arundhati Parmar, Personify Health Chief Medical Officer Jeff Jacques talks about the different types of GLP-1 drugs, what portion of employers currently offer the medications, and how many employers are considering making them part of their health benefit offering in the future. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe